March 2025

Carelon Research will be joining more than 4,000 managed care decision makers at AMCP 2025 in Houston, Texas. Connect with our experts and see our latest research.

Carelon Research presentations

Carelon Research authors are indicated in bold.
*Associate at time of study

Presentation

Session

Title

Authors

Affiliations

Poster Presentation

Wednesday, April 2, 2025
11:30 AM – 1:00 PM 
Expo Hall

AMCP Poster Session

[C11] Real-world outcomes for pembrolizumab and nivolumab monotherapy in patients with metastatic or unresectable melanoma

Price A[1], Ball P[1], Barron J[1], Ketkar A[1], Rusin S[2], Sefain H[2]

[1]Carelon Research, Wilmington, DE, USA, [2]CarelonRx, Morristown, NJ, USA

Poster Presentation

Wednesday, April 2, 2025
11:30 AM – 1:00 PM
Expo Hall

AMCP Poster Session

[E14] Diagnostic journey of patients with type 1 diabetes with and without a prior type 2 diabetes misdiagnosis in a US manage care population

Brixner D[1], Beyene TJ[2], Venkataraman M[2], Teng CC[2], Tan H[2], Wilson [3], Cagle A [3], Malone DC[1]

[1]University of Utah College of Pharmacy, Salt Lake City, UT, USA [2]Carelon Research, Wilmington, DE, USA, [3]Sanofi, Bridgewater, NJ, USA  

Platinum Ribbon Poster

Wednesday, April 2, 2025
11:30 AM – 1:00 PM
Expo Hall

AMCP Poster Session

[C2] Real-world bevacizumab biosimilar uptake from 2018-2023 and outcomes among patients with NSCLC and mCRC using commercial and Medicare Advantage claims in the US  

Dixon RW[1], Venkataraman M[1], Barron J[1], Harris K[1], Pithua P[2], Roth JA[3], Mendelsohn AB[4], Yee G[5], Li MS[6], Lockhart C[2]

[1]Carelon Research, Wilmington, DE, USA, [2] Biologics & Biosimilars Collective Intelligence Consortium, Alexandria, VA, USA, [3]Pfizer Inc., New York, NY, USA, [4]Harvard Pilgrim Health Care Institute, Boston, MA, USA, [5]University of Nebraska Medical Center, Omaha, NE, USA, [6]University of Tennessee Health Science Center, Memphis, TN, USA  

Platinum Ribbon Podium

Tuesday, April 1, 2025
3:15 – 4:30 PM
310

(R3) Research podium session – leveraging real-world data to advance managed care pharmacy practice

[310] What is the real-world uptake of bevacizumab biosimilars from 2018 to 2023? 

Dixon RW[1], Venkataraman M[1], Barron J[1], Harris K[1], Lockhart CM[2]

[1]Carelon Research, Wilmington, DE, USA, [2] Biologics & Biosimilars Collective Intelligence Consortium, Alexandria, VA, USA